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Introduction
Posterior polymorphous corneal dystrophy (PPCD) is an autosomal dominant disorder characterized by the presence of characteristic corneal endothelial opacities as well as corneal steepening. While the majority of affected individuals are thought to be asymptomatic, the percentage of individuals who require corneal transplantation for corneal edema is estimated to be approximately 20%-25%, significantly higher than previously believed. [1] PPCD demonstrates genetic heterogeneity, having been mapped to both chromosome 10 (PPCD3 locus) and 20 (PPCD1 locus). To date, approximately 30% to 40% of PPCD cases have been attributed to 40 unique heterozygous nonsense and frameshift mutations and hemizygous copy number variants involving the zinc finger E-box binding homeobox 1 gene (ZEB1) on chromosome 10 that likely result in ZEB1 haploinsufficiency. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, the identification of the genetic basis of PPCD1 (MIM ID #122000) has proven to be more elusive, in spite of the fact that linkage to the PPCD1 locus was reported almost a decade before linkage to the PPCD3 locus was described. [13, 14] A 3.6 cM (1.8 Mb) interval is shared between four PPCD families that demonstrated linkage to the pericentromeric region of chromosome 20. [13, [15] [16] [17] [18] [19] [20] However, mutational analysis of the coding sequence and exon-intron boundaries of the 32 positional candidate genes from the shared interval failed to identify a pathogenic mutation in one of the four families linked to the PPCD1 locus. [15] [16] [17] [19] [20] [21] [22] [23] Given this, we employed a targeted next-generation sequencing approach to identify potentially pathogenic non-coding variants in these 32 positional gene candidates. We identified 11 single-nucleotide variants (SNV) in nine genes that met our criteria of possible pathogenicity. Four of the SNVs were located in three different protein coding genes, three of which (OVOL2 c.327C>A, OVOL2 c.-307T>C, and THBD c.351A>G) segregated with the affected status when additional family members who did not undergo NGS were screened. Of these, only c.-307T>C, in the promoter region of the ovolike zinc finger 2 (OVOL2) gene, was novel, and was not identified in 100 controls. [24] Davidson and colleagues recently reported the identification of c.-307T>C and two other novel OVOL2 promoter region variants (c.-274T>G and c.-370T>C) in two British and 16 Czech PPCD families, which include two of the four families that have been previously mapped to the PPCD1 locus. [25] In addition, another OVOL2 promoter region variant (c.-339_361dup) was identified in a family originally reported with autosomal dominant congenital hereditary endothelial dystrophy (CHED) mapped to the CHED1 locus, which overlaps the PPCD1 locus. [25] OVOL2 is a transcription factor that has been shown to downregulate ZEB1 expression, thereby suppressing EMT and driving mesenchymal-to-epithelial transition (MET) instead. [26, 27] Reporter activity assays using OVOL2 promoter constructs each containing one of the four identified variants demonstrated increased in vitro reporter gene expression compared to the wild type promoter in HEK293 cells. [25] Thus, Davidson and colleagues proposed that PPCD-associated OVOL2 promoter variants cause increased OVOL2 expression and the encoded protein subsequently represses ZEB1 expression, leading to a PPCD phenotype similar to PPCD3, in which ZEB1 truncating mutations likely result in ZEB1 haploinsufficiency. [4, 12] Herein, we present the results of sequencing the 5' UTR and promoter region of OVOL2 in the family originally linked to the PPCD1 locus on chromosome 20, as well as in 26 PPCD probands in whom a ZEB1 truncating mutation was not identified. [13] We also report the results of copy number variation (CNV) analysis in the PPCD1 and PPCD3 loci to identify the cause of PPCD in individuals without either an OVOL2 or a ZEB1 5' UTR, promoter, or coding region mutation. In addition, we present the results of in vitro promoter assays in human corneal endothelial cells to confirm the functional impact of the pathogenic OVOL2 promoter variant in the affected cell type.
Materials and Methods
This study followed the Declaration of Helsinki and was approved by the Institutional Review Board at the University of California at Los Angeles (UCLA IRB# 94-07-243-(14-33A), 02-10-092-(4,11),11-000020). Informed written consent was obtained from all subjects in this study.
Patient selection and DNA collection
Individuals with PPCD were examined with slit lamp biomicroscopic imaging and the diagnosis of PPCD was made based upon previously described clinical characteristics. [3] After informed consent was obtained, genomic DNA was purified from peripheral blood leukocytes using the FlexiGene DNA Isolation Kit (Qiagen, Valencia, CA) or extracted from buccal epithelial cells using the Oragene Saliva Collection Kit (DNA Genotek, Ottawa, Canada) according to the manufacturer's instructions.
ZEB1-Polymerase chain reaction (PCR) and Sanger sequencing
Each of the nine exons of ZEB1, including an alternative exon 1, as well as the 1 kb region upstream of the initiation methionine (ATG), were amplified using previously described primers and conditions. [8] Following purification of the PCR products, sequencing reactions were performed using a previously described protocol and then analyzed on an ABI-3100 Genetic Analyzer (Applied Biosystems). [8] Sequences for the 1 kb region upstream of translational start site were compared to the ZEB1 RefSeqGene sequence (GenBank accession number NG_017048.1). Based on the annotation of ZEB1 transcript NM_030751.5, the promoter region was defined as the sequences upstream of the transcriptional start site (c.-452) and the 5' UTR was defined as the region between the transcriptional start site (c.-452) and the translational start site (c.1). Coding region nucleotide sequences (including the donor and acceptor splice sites) were read manually by comparison to the ZEB1 cDNA sequences (GenBank accession number NM_030751 and NM_001128128.2). The description of the identified sequence variants adhered to the Human Genome Variation Society (HGVS) nomenclature guidelines.
OVOL2-Polymerase chain reaction (PCR) and Sanger sequencing
Each of the four OVOL2 coding exons and the 1.8kb region upstream of the OVOL2 translational start site (containing both the 5' UTR and promoter) were amplified and screened using previously described primer sequences as well as custom designed primers (S1 Table) . [25] Based on Genbank OVOL2 transcript NM_021220.3, the promoter region was defined as the sequences upstream of the transcriptional start site (c.-248) and the 5' UTR was defined as the region between the transcriptional start site (c.-248) and the translational start site (c.1). PCR reactions were performed using GoTaq 
CNV analysis in PPCD1 and PPCD3 loci
Genomic DNA samples from eight PPCD probands in whom a ZEB1 mutation was not identified were submitted to the UCLA Clinical Microarray Core for array comparative genome hybridization (aCGH) to identify copy number variation (CNV) using a custom Agilent 8x60K array (Agilent Technologies, Inc., Santa Clara, CA , or empty (pGL3-Basic) promoter luciferase construct (generously provided by Dr. Alison J. Hardcastle of the University College London). [25] To measure differences in transfection efficiency between wells, 250 ng of pGL4.75
[hRluc_CMV] (Promega) was added to each transfection for a total of 500 ng of plasmid DNA per transfection. Forty-eight hours post-transfection, cells were lysed with 100 μL of Passive Lysis Buffer (Promega). Protein levels from cell lysates were quantified using the Pierce™ BCA Protein Assay Kit (Life Technologies) and FilterMax F5 microplate reader (Molecular Devices, Sunnyvale, CA). Promoter activity was measured using the Dual-luciferase 1 Reporter Assay System (Promega) according to manufacturer's instructions. Each trial was normalized to Renilla firefly luminescence in order to account for variability in transfection efficiency.
Statistical analyses
The probability and corresponding 95% confidence interval of the identified variant, c.-1409G>C, found within the screened probands was estimated based on the observed frequency in the probands and from the observed frequency of same variant in the population assuming binomial distribution of allele frequencies.
Results

Screening of ZEB1 coding, 5'UTR, and promoter regions in PPCD probands
We have previously reported the absence of presumed pathogenic variants in the non-coding 1 kb region (containing both the 5' UTR and promoter) upstream of the ZEB1 translational start site in 31 PPCD probands without a ZEB1 coding region mutation. [8] After six additional PPCD probands without a ZEB1 coding region mutation were identified, we screened the 1 kb upstream of the initiation methionine in these six individuals. The known single nucleotide polymorphism (SNP) c.-803G>C (rs3737180; minor allele frequency (MAF) 0.316) was identified in the heterozygous state in two individuals, one of whom also demonstrated a second known SNP (c.-933T>G (rs3737179; MAF 0.316)) in the heterozygous state. Of the 37 DNA samples from these individuals without a ZEB1 promoter, 5' UTR, or coding mutation, 27 had sufficient DNA to analyze the 1.8kb region upstream of the OVOL2 translational start site.
Exclusion of pathogenic OVOL2 coding, 5'UTR, and promoter region variants in genetically unresolved PPCD probands
Of the 27 probands who had sufficient DNA to perform screening of the OVOL2, one proband (P1) is a member of the family that we mapped to the PPCD1 locus and in which we identified a OVOL2 promoter variant (c.-307T>C) that segregated with the affected phenotype. [18, 24] Screening of the 1.8 kb region upstream of the translational start site of OVOL2 in the remaining 26 PPCD probands in whom a ZEB1 truncating mutation was not identified revealed five different heterozygous variants in eight probands, while the remaining 18 probands did not demonstrate any heterozygous variants within either the OVOL2 promoter or 5' UTR (Table 1) . Of the five identified variants, only one, c.-61G>A, was either novel or rare (MAF 0.01). However, the c.-61G>A variant, identified in a single proband (P3), was not identified in his affected father, indicating that it was not causative of PPCD. The only variant identified in more than one proband, c.-1409G>C, has a global MAF of 0.0541. Although the observed frequency of the c.-1409G>C variant in the 27 probands who had sufficient DNA to perform screening of the OVOL2 promoter (6/54 chromosomes corresponding to an observed MAF of 0.111) was double the global MAF of 0.0541, the difference was not statistically significant (p = 0.064). Given this, and as the global minor allele frequency is much higher than the population prevalence of PPCD, the c.-1409G>C variant is very unlikely to be pathogenic. Screening of each of the four OVOL2 coding exons in the 27 probands revealed only one heterozygous variant (c.327C>A), which was identified in three probands. As the c.327C>A variant has a MAF of 0.0403, much higher than the population prevalence of PPCD, this variant is also very unlikely to be pathogenic.
Identification and segregation of OVOL2 promoter variant c.-307T>C in the family originally mapped to the PPCD1 locus on chromosome 20
The 1.8 kb region upstream of the translational start site of OVOL2 was screened in affected and unaffected members of the family with PPCD that was the first to be mapped to the PPCD1 locus on chromosome 20 (Fig 1) . [13] Within the promoter region, the c.-307T>C variant was identified in each of the 20 affected family members and was not identified in 12 of the 14 unaffected members who were screened (Fig 1) .
No copy number variation identified in PPCD1 or PPCD3 loci CNV analysis within the PPCD1 and PPCD3 loci was performed in eight of the 27 PPCD probands without a ZEB1 or OVOL2 coding, 5' UTR, or promoter region mutation to evaluate for the presence of a potentially pathogenic structural variation. In the PPCD1 locus, 11 CNVs (4 gains and 7 losses) were identified in five of the eight probands, ranging in size from 134 to 14,007 base pairs (S2 Table) . Three of the 11 CNVs involved protein-coding genes: two overlapping CNV gains in intron 1 of XRN2, with one gain present in one (1/8) proband, and the second gain present in three (3/8) probands; and a loss in intron 2 of PIGU, which was identified in three (3/8) probands. There were no identified CNVs within OVOL2. In the PPCD3 locus, CNV were identified in eight genomic regions, although none involved ZEB1. ). While both OVOL2 P WT and OVOL2 P c.-307T>C were able to drive the expression of luciferase, OVOL2 P c.-307T>C produced significantly higher levels of luciferase expression when compared to the OVOL2 P WT (Fig 2) .
Discussion
The recent identification of OVOL2 promoter mutations associated with PPCD by Davidson and colleagues as well as our group has led us to screen the OVOL2 5' UTR and promoter region in the family in which linkage analysis established the PPCD1 locus on chromosome 20 and in an additional 26 probands in whom a ZEB1 truncating mutation was not identified. [24, 25] We identified the same c.-307T>C variant within affected members of the family that Heon and colleagues mapped to the PPCD1 locus as in the family that we subsequently mapped to an overlapping interval. [13, 18] Although the c.-307T>C was found in two unaffected family members (VI-3 and VI-4), these two individuals were first evaluated in their twenties and were not available for re-examination. Therefore, their affected status cannot be confirmed. In this pedigree, the average age at the time of diagnosis of PPCD was 25 years, with a range between 4 and 40 years. [13] Given that the c.-307T>C variant segregates with the affected phenotype in the other 32 affected and unaffected individuals screened, as well as in the 29 individuals in our PPCD1-linked family, the overwhelming likelihood is that these two individuals are in fact affected. [24] This variant has now been demonstrated to segregate with the affected phenotype in three unrelated families that have all been mapped to the PPCD1 locus. Given this, as well as the fact that three other variants in the OVOL2 promoter have been shown to segregate with the affected phenotype in two other families with PPCD (including the fourth family previously mapped to the PPCD1 locus) and one family initially diagnosed with autosomal dominant CHED that was mapped to the region on chromosome 20 containing OVOL2, promoter mutations in OVOL2 have been convincingly associated with PPCD1. [24, 25] Our failure to identify a presumed pathogenic OVOL2 or ZEB1 coding region or promoter mutation or CNV involving either gene in 26 PPCD probands indicates that other genes may be associated with PPCD. In the PPCD mouse, a chromosomal inversion flanked by deletions involving Csrp2bp and Dzank1 has been identified in the portion of chromosome 2 that is syntenic to the human PPCD1 locus. [28, 29] The investigators reported the upregulation of two Csrp2bp fusion transcripts and Ovol2, which is located 37 kb from Csrp2bp and 66 kb from the breakpoint of the chromosomal inversion. While it is possible that the identified genetic rearrangement leads to PPCD1 in the mouse through upregulation of Ovol2 expression, as is the case in humans, the authors provide compelling evidence for the disruption of Csrp2bp as being causative for PPCD1 in the mouse. [28, 29] However, we did not detect CNV involving the human ortholog CSRP2BP in any of the 8 probands analyzed for CNV. Although identification of other affected pedigrees of sufficient size to perform whole exome sequencing and CNV analysis to identify additional genetic loci should be performed, we also plan to perform and encourage other investigators to perform sequencing of presumed OVOL2 and ZEB1 regulatory sequences to identify other potentially pathogenic sequence variants.
Additional studies will also need to be performed to elucidate the role of OVOL2 in the corneal endothelium, and to determine whether OVOL2 acts to repress the expression of ZEB1, as it does in corneal epithelial cells. OVOL2 maintains the epithelial cell state by repressing mesenchymal genes such as ZEB1. [27] When cotransduced with PAX6, OVOL2 induces the transcriptional profile of corneal epithelial cells in fibroblasts, suggesting that OVOL2 may serve as a master regulator of the epithelial cell state. [27] In contrast, the roles, if any, that OVOL2 plays in corneal endothelial cell differentiation, function, and dysfunction are virtually unstudied. Here, we demonstrate that the c.-307T>C variant in OVOL2 results in enhanced promoter activity in corneal endothelial cells compared to the wild-type sequence. As it has been previously reported that OVOL2 represses ZEB1 expression, our promoter activity results are consistent with the hypothesis that PPCD-associated OVOL2 promoter mutations lead to PPCD by causing OVOL2 overexpression and subsequent ZEB1 insufficiency. [26, 27] In silico analyses have predicted PPCD-associated OVOL2 promoter mutations cause a gain or loss of putative transcription factor binding sites, potentially leading to OVOL2 dysregulation. [24, 25] Further investigation into the effects of PPCD-associated OVOL2 and ZEB1 mutations on the expression of these transcription factors, the endothelial transcriptome and corneal endothelial morphology and function are ongoing, and are anticipated to clarify whether both PPCD1 and PPCD3 share a common molecular pathway. 
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